The STRIVE data will be presented at the European Academy of Neurology (EAN) annual meeting in Oslo, Norway.
News
PhoreMost, C4X Discovery announce neurodegeneration collaboration
The collaboration will initially accelerate C4X Discovery’s Parkinson’s disease drug discovery pipeline.
New Herceptin combo could keep breast cancers at bay
Guiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin is effective at treating women with breast cancer who have no other treatment options.
MHRA licenses two jet-lag treatments
The medicines can now satisfy a previously unmet clinical need, in an area where where patient demand is high.
Pharma ranked a highest contributor to society, despite public perception
The data found that the pharmaceutical industry adds much more value than most sectors.
UK ‘running out of time’ to eliminate no-deal Brexit disruption
Niall Dickson, chief executive of the NHS Confederation, expressed concerns about the plans.
FDA approves Dupixent, Darzalex, Soliris
Dupixent is the first and only biologic treatment for adults with chronic rhinosinusitis with nasal polyposis.
Finals day location confirmed for the 2019 Medical & Scientific Excellence Awards
PharmaTimes are pleased to announce that this year’s finals day challenges will be taking place at the IQVIA offices based in Reading on the 5th December 2019 – with the awards ceremony taking place later that evening at a TBA venue.
Cervical cancer eradication a possibility, finds new report
After five to eight years of vaccination, the prevalence of HPV 16 and 18 decreased significantly by 83% in girls aged 13 to 19 years.
New prostate cancer test could diagnose five years earlier
Previous urine biomarker tests have been designed specifically for single purposes such as the detection of prostate cancer on re-biopsy.
NICE explores extending use of real world data to inform guidance
A consultation has begun on NICE’s Statement of Intent.
Imfinzi found to improve survival in small cell lung cancer
Limited treatment options are available for patients with this most aggressive type of lung cancer.
Cosentyx successful in plaque psoriasis trial
The drug successfully modulates gene expression, leading to substantial improvement of inflammation.
Oxford Biomedica, Santen enter retinal disease R&D alliance
Inherited retinal diseases are ideal candidates for gene therapy because many of the responsible genetic mutations have already been identified.
NICE publishes draft guidance on adult leg ulcers
Overuse of antimicrobials is contributing to a global threat of worldwide antimicrobial resistance.
